BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 01 giu, 2012
    Sommario
    A strategic alliance on anti-cancer drugs between NERVIANO and IEO
    Cell Therapeutics’ Pixuvri Approved in European Union as monotherapy to treat adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-Cell Lymphomas
    Cell Therapeutics enters into agreement to acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
    New England Journal of Medicine reports on three Phase III Revlimid (lenalidomide) trials in patients with newly diagnosed multiple myeloma
  • 02 mag, 2012
    Sommario
    Abcodia and Biouniversa announce collaboration on BAG3 biomarker for the early detection of pancreatic cancer
    A collaboration between Heinz and IEO gives birth to a new generation of infant food
    NicOx appoints Philippe Masquida EVP, Managing Director of European Operations
  • 01 apr, 2012
    Sommario
    NicOx, Bausch + Lomb Glaucoma Candidate BOL-303259-X Meets Primary Endpoint in Phase 2b Study
    NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business
    Axxam receives EUR 2.3 million grant from the Italian Ministry of Research to support innovative drug discovery programs
    Aptuit Verona invests on a preclinical cardiac safety panel
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 01 mar, 2012
    Sommario
    Dompé to acquire 100% of Anabasis, an Italian biopharmaceutical ophthalmology company
    The Link Campus University has established the BioLink Institute in Rome
    European Medicines Agency's Committee For Medicinal Products For Human Use issues positive opinion for conditional Approval on marketing authorization application for Pixuvri
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 01 feb, 2012
    Sommario
    Rheumatoid arthritis: soon on the market a new kit for the diagnosis
    thanks to the collaboration between Toscana Biomarkers and DIESSE Ricerche
    TTFactor and OncoMed Pharmaceuticals Inc. sign an agreement for advancing novel cancer therapies through IEO scientific expertise
    AB ANALITICA launches a simple and fast kit for the detection of all HLA haplotypes associated with Celiac Disease, using Reverse Line Blot Protocol and dedicated software for interpretation of results
    Axxam awarded with EUR 0.5 million by the Lombardy Region to support an innovative high throughput method for  early “in vitro” safety risk assessment of compounds.
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 08 gen, 2012
    Sommario
    A Strategic International Health Care Event (10th February 2012, Milano - Italy)
    Italian Biotech meets Investors in Milan (BioInItaly, April 18-19)
    UK–Italy Business Awards Ceremony
  • 02 dic, 2011
    Sommario
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 03 nov, 2011
    Sommario
    Fast Forward, Juvenile Diabetes Research Foundation and Axxam renew their partnership to accelerate development of treatments for multiple sclerosis and type 1 diabetes
    Adienne’s Mubodina patented by EPO and USPTO
    Genovax completes the Phase I/II clinical study for GX301
    MolMed expands Phase III trial of NGR-hTNF for the treatment of mesothelioma in the United States
    Phase II study evaluating Abraxane® clinical potential in patients with advanced pancreatic cancer published in the Journal of Clinical Oncology online
    Independent radiology assessment panel results confirm statistical significance of response and progression endpoints of Cell Therapeutics’ Pixantrone PIX301 Pivotal Trial
  • 03 ott, 2011
    Sommario
    Tools of Science, new tool for life science professionals
    NicOx: new preclinical data for NCX 6560
    Key European patent for MolMed’s TK cell therapy
    Axxam receives funding for the development of compounds for prevention treatment of disability in Multiple Sclerosis
    MolMed presents new data from four clinical trials on NGR-hTNF at European Multidisciplinary Cancer Congress
    Axxam and Polyphor participate in a Research Partnership for the Treatment of Type-2 Diabetes Funded by the EU
  • 29 lug, 2011
    Sommario
    A Further Milestone Reached in the Collaboration Between Siena Biotech and Roche
    Siena Biotech S.p.A
    Monitoring the lipid composition of cell culture membranes: a special price for ReMembrane
  • 07 giu, 2011
    Sommario
    METGEN and SPRIN: Biocatalysis for the Future
    MolMed: Results of three Phase II trials in lung cancer indications confirm safety and antitumour activity of NGR-hTNF
    Areta successfully selected for Italia degli Innovatori 2011/2012
  • 05 mag, 2011
    Sommario
    Siena Biotech announces Start of Phase II Studies with SEN0014196 for Huntington’s Disease
    NicOx withdraws its marketing authorization application for naproxcinod in Europe
    Otsuka establishes Otsuka Pharmaceutical Italy S.r.l.
    Cell Therapeutics acquires exclusive marketing and co-development rights in the Americas to Chroma Therapeutics’Tosedostat